Browse > Article
http://dx.doi.org/10.5483/BMBRep.2019.52.9.094

ACOX1 destabilizes p73 to suppress intrinsic apoptosis pathway and regulates sensitivity to doxorubicin in lymphoma cells  

Zheng, Fei-Meng (Department of Medical Oncology, The Eastern Hospital, The First Affiliated Hospital, Sun Yat-sen University)
Chen, Wang-Bing (Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology)
Qin, Tao (Department of Medical Oncology, Sun Yat-sen Hospital, Sun Yat-sen University)
Lv, Li-Na (Department of Hematology, Wuming Hospital of Guangxi Medical University)
Feng, Bi (Department of Medical Oncology, The Eastern Hospital, The First Affiliated Hospital, Sun Yat-sen University)
Lu, Yan-Ling (Department of Medical Oncology, The Eastern Hospital, The First Affiliated Hospital, Sun Yat-sen University)
Li, Zuo-Quan (Department of Ultrasound, Guancheng Hospital)
Wang, Xiao-Chao (Department of Hematology, Affiliated Hospital of Youjiang Medical University for Nationalities)
Tao, Li-Ju (Department of Hematology, Wuming Hospital of Guangxi Medical University)
Li, Hong-Wen (Department of Hematology, Wuming Hospital of Guangxi Medical University)
Li, Shu-You (Department of Medical Oncology, Wuming Hospital of Guangxi Medical University)
Publication Information
BMB Reports / v.52, no.9, 2019 , pp. 566-571 More about this Journal
Abstract
Lymphoma is one of the most curable types of cancer. However, drug resistance is the main challenge faced in lymphoma treatment. Peroxisomal acyl-CoA oxidase 1 (ACOX1) is the rate-limiting enzyme in fatty acid ${\beta}$-oxidation. Deregulation of ACOX1 has been linked to peroxisomal disorders and carcinogenesis in the liver. Currently, there is no information about the function of ACOX1 in lymphoma. In this study, we found that upregulation of ACOX1 promoted proliferation in lymphoma cells, while downregulation of ACOX1 inhibited proliferation and induced apoptosis. Additionally, overexpression of ACOX1 increased resistance to doxorubicin, while suppression of ACOX1 expression markedly potentiated doxorubicin-induced apoptosis. Interestingly, downregulation of ACOX1 promoted mitochondrial location of Bad, reduced mitochondrial membrane potential and provoked apoptosis by activating caspase-9 and caspase-3 related apoptotic pathway. Overexpression of ACOX1 alleviated doxorubicin-induced activation of caspase-9 and caspase-3 and decrease of mitochondrial membrane potential. Importantly, downregulation of ACOX1 increased p73, but not p53, expression. p73 expression was critical for apoptosis induction induced by ACOX1 downregulation. Also, overexpression of ACOX1 significantly reduced stability of p73 protein thereby reducing p73 expression. Thus, our study indicated that suppression of ACOX1 could be a novel and effective approach for treatment of lymphoma.
Keywords
ACOX1; Apoptosis; Doxorubicin; Drug resistance; Lymphoma; p73; Protein degradation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Huh J (2012) Epidemiologic overview of malignant lymphoma. Korean J Hematol 47, 92-104   DOI
2 Smith A, Crouch S, Lax S et al (2015) Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer 112, 1575-1584   DOI
3 Shanbhag S and Ambinder RF (2018) Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 68, 116-132   DOI
4 Armitage JO, Gascoyne RD, Lunning MA and Cavalli F (2017) Non-Hodgkin lymphoma. Lancet 390, 298-310   DOI
5 Zeng J and Li D (2004) Expression and purification of his-tagged rat peroxisomal acyl-CoA oxidase I wild-type and E421 mutant proteins. Protein Expr Purif 38, 153-160   DOI
6 Fournier B, Saudubray JM, Benichou B et al (1994) Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy. J Clin Invest 94, 526-531   DOI
7 Fan CY, Pan J, Chu R et al (1996) Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 271, 24698-24710   DOI
8 Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS and Reddy JK (1998) Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273, 15639-15645   DOI
9 Huang J, Viswakarma N, Yu S et al (2011) Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am J Pathol 179, 703-713   DOI
10 Melino G, De Laurenzi V and Vousden KH (2002) p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2, 605-615   DOI
11 Oberst A, Rossi M, Salomoni P et al (2005) Regulation of the p73 protein stability and degradation. Biochem Biophys Res Commun 331, 707-712   DOI
12 Jones EV, Dickman MJ and Whitmarsh AJ (2007) Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J 405, 617-623   DOI
13 Nemajerova A, Petrenko O, Trumper L, Palacios G and Moll UM (2010) Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J Clin Invest 120, 2070-2080   DOI
14 Zorova LD, Popkov VA, Plotnikov EY et al (2018) Mitochondrial membrane potential. Anal Biochem 552, 50-59   DOI
15 Chao C, Herr D, Chun J and Xu Y (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 25, 2615-2622   DOI
16 Antonenkov VD, Grunau S, Ohlmeier S and Hiltunen JK (2010) Peroxisomes are oxidative organelles. Antioxid Redox Signal 13, 525-537   DOI
17 Dahabieh MS, Di Pietro E, Jangal M et al (2018) Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism. Biochim Biophys Acta Rev Cancer 1870, 103-121   DOI
18 Dahabieh MS, Ha Z, Di Pietro E et al (2017) Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death Differ 24, 1912-1924   DOI
19 Ferdinandusse S, Denis S, Hogenhout EM et al (2007) Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat 28, 904-912   DOI
20 Yu S, Rao S and Reddy JK (2003) Peroxisome proliferatoractivated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Curr Mol Med 3, 561-572   DOI
21 Asher G, Tsvetkov P, Kahana C and Shaul Y (2005) A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev 19, 316-321   DOI
22 Hashimoto T, Fujita T, Usuda N et al (1999) Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 274, 19228-19236   DOI
23 Rossi M, De Laurenzi V, Munarriz E et al (2005) The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24, 836-848   DOI
24 Miyazaki K, Ozaki T, Kato C et al (2003) A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem Biophys Res Commun 308, 106-113   DOI
25 Agami R, Blandino G, Oren M and Shaul Y (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399, 809-813   DOI
26 Zheng F, Yue C, Li G et al (2016) Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nat Commun 7, 10180   DOI
27 Zheng FM, Long ZJ, Hou ZJ et al (2014) A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance. Mol Cancer Ther 13, 1991-2003   DOI